AR080143A1 - Pirrolidina-2-carboxamidas sustituidas, composicion farmaceutica que las contiene y su uso en el tratamiento de tastornos oncologicos - Google Patents
Pirrolidina-2-carboxamidas sustituidas, composicion farmaceutica que las contiene y su uso en el tratamiento de tastornos oncologicosInfo
- Publication number
- AR080143A1 AR080143A1 ARP110100393A ARP110100393A AR080143A1 AR 080143 A1 AR080143 A1 AR 080143A1 AR P110100393 A ARP110100393 A AR P110100393A AR P110100393 A ARP110100393 A AR P110100393A AR 080143 A1 AR080143 A1 AR 080143A1
- Authority
- AR
- Argentina
- Prior art keywords
- ch2ch2o
- substituted
- unsubstituted
- cycloalkenyl
- cycloalkyl
- Prior art date
Links
- 230000000771 oncological effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, ethynyl Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Estos compuestos son utiles como agentes anticancerosos. Reivindicacion 1: Los compuestos de la formula (1) en la que X se elige entre el grupo formado por H, F, Cl, Br, I, ciano, nitro, etinilo, ciclopropilo, metilo, etilo, isopropilo, vinilo y metoxi; Y es de uno a cuatro restos elegidos con independencia entre el grupo formado por H, F, Cl, Br, I, CN, OH, nitro, alquilo inferior, cicloalquilo, alcoxi inferior, alquenilo inferior, cicloalquenilo, alquinilo inferior, arilo, heteroarilo, heterociclo, COOR', OCOR', CONR'Rö, NR'CORö, NRöSO2R', SO2NR'Rö y NR'Rö, en los que R' y Rö se eligen con independencia entre H, alquilo inferior sustituido o sin sustituir, cicloalquilo inferior sustituido o sin sustituir, alquenilo inferior sustituido o sin sustituir, cicloalquenilo inferior sustituido o sin sustituir, arilo sustituido o sin sustituir, heteroarilo sustituido o sin sustituir y heterociclo sustituido o sin sustituir; y en el caso de que R' y R'' puedan unirse de modo independiente para formar una estructura cíclica elegida entre cicloalquilo sustituido o sin sustituir, cicloalquenilo sustituido o sin sustituir, heteroarilo sustituido o sin sustituir y heterociclo sustituido o sin sustituir, uno de R1 y R2 se elige entre el grupo formado por alquilo inferior, alquilo inferior sustituido, alquenilo inferior, alquenilo inferior sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo, heterociclo sustituido, cicloalquilo, cicloalquilo sustituido, cicloalquenilo y cicloalquenilo sustituido y el otro es hidrogeno o alquilo inferior; R3 es H o alquilo inferior; uno de R4 y R5 se elige entre el grupo formado por alquilo inferior, alquilo inferior sustituido, alquenilo inferior, alquenilo inferior sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo, heterociclo sustituido, cicloalquilo, cicloalquilo sustituido, cicloalquenilo y cicloalquenilo sustituido y el otro es hidrogeno; R6 y R7 se eligen entre el grupo formado por (CH2)n-R', (CH2)n-NR'Rö, (CH2)n-NR'CORö, (CH2)n-NR'SO2Rö, (CH2)n-COOH, (CH2)n-COOR', (CH2)n-CONR'Rö, (CH2)n-OR', (CH2)n-SR', (CH2)n-SOR', (CH2)n-SO2R', (CH2)n-COR', (CH2)n-SO3H, (CH2)n-SONR'Rö, (CH2)n-SO2NR'Rö, (CH2CH2O)m-(CH2)n-R', (CH2CH2O)m-(CH2)n-OH, (CH2CH2O)m-(CH2)n-OR', (CH2CH2O)m-(CH2)n-NR'Rö, (CH2CH2O)m-(CH2)n-NR'CORö, (CH2CH2O)m-(CH2)n-NR'SO2Rö, (CH2CH2O)m-(CH2)n-COOH, (CH2CH2O)m-(CH2)n-COOR', (CH2CH2O)m-(CH2)n-CONR'Rö, (CH2CH2O)m-(CH2)n-SO2R', (CH2CH2O)m-(CH2)n-COR', (CH2CH2O)m-(CH2)n-SONR'Rö, (CH2CH2O)m-(CH2)n-SO2NR'Rö, (CH2)p-(CH2CH2O)m-(CH2)n-R', (CH2)p-(CH2CH2O)m-(CH2)n-OH, (CH2)p-(CH2CH2O)m-(CH2)n-OR', (CH2)p-(CH2CH2O)m-(CH2)n-NR'Rö, (CH2)p-(CH2CH2O)m-(CH2)n-NR'CORö, (CH2)p-(CH2CH2O)m-(CH2)n-NR'SO2Rö, (CH2)p-(CH2CH2O)m-(CH2)n-COOH, (CH2)p-(CH2CH2O)m-(CH2)n-COOR', (CH2)p-(CH2CH2O)m-(CH2)n-CONR'Rö, (CH2)p-(CH2CH2O)m-(CH2)n-SO2R', (CH2)p-(CH2CH2O)m-(CH2)n-COR', (CH2)p-(CH2CH2O)m-(CH2)n-SONR'Rö, (CH2)p-(CH2CH2O)m-(CH2)n-SO2NR'Rö, -COR', -SOR' y SO2R', en los que R' y Rö tienen los significados definidos anteriormente; m, n y p son con independencia un numero de 0 a 6; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/702,402 US8354444B2 (en) | 2008-09-18 | 2010-02-09 | Substituted pyrrolidine-2-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080143A1 true AR080143A1 (es) | 2012-03-14 |
Family
ID=43608850
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100393A AR080143A1 (es) | 2010-02-09 | 2011-02-07 | Pirrolidina-2-carboxamidas sustituidas, composicion farmaceutica que las contiene y su uso en el tratamiento de tastornos oncologicos |
ARP180103640A AR114159A2 (es) | 2010-02-09 | 2018-12-13 | Pirrolidina-2-carboxamidas sustituidas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103640A AR114159A2 (es) | 2010-02-09 | 2018-12-13 | Pirrolidina-2-carboxamidas sustituidas |
Country Status (32)
Country | Link |
---|---|
US (1) | US8354444B2 (es) |
EP (1) | EP2534132B1 (es) |
JP (1) | JP5612710B2 (es) |
KR (1) | KR101461298B1 (es) |
CN (1) | CN102753522B (es) |
AR (2) | AR080143A1 (es) |
AU (1) | AU2011214506C1 (es) |
BR (1) | BR112012019672B1 (es) |
CA (1) | CA2788236C (es) |
CL (1) | CL2012002189A1 (es) |
CR (1) | CR20120410A (es) |
CY (1) | CY1119049T1 (es) |
DK (1) | DK2534132T3 (es) |
EC (1) | ECSP12012083A (es) |
ES (1) | ES2629439T3 (es) |
HK (1) | HK1171452A1 (es) |
HR (1) | HRP20170903T1 (es) |
HU (1) | HUE034816T2 (es) |
LT (1) | LT2534132T (es) |
MX (1) | MX2012009186A (es) |
MY (1) | MY165238A (es) |
NZ (1) | NZ601422A (es) |
PE (1) | PE20121532A1 (es) |
PL (1) | PL2534132T3 (es) |
PT (1) | PT2534132T (es) |
RS (1) | RS56163B1 (es) |
RU (1) | RU2564022C2 (es) |
SG (1) | SG182763A1 (es) |
SI (1) | SI2534132T1 (es) |
TW (1) | TWI401243B (es) |
UA (1) | UA107954C2 (es) |
WO (1) | WO2011098398A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7303676B2 (en) * | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
RS57158B1 (sr) | 2011-03-10 | 2018-07-31 | Daiichi Sankyo Co Ltd | Dispiropirolidinski derivat |
EP2771008A4 (en) | 2011-10-28 | 2015-04-08 | Merck Sharp & Dohme | MACROCYCLES INCREASING P53 ACTIVITY AND USES THEREOF |
EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US20140200255A1 (en) * | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
RU2014150492A (ru) * | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
PE20151335A1 (es) * | 2013-01-22 | 2015-09-18 | Hoffmann La Roche | Composicion farmaceutica con biodisponibilidad mejorada |
BR112015015880B1 (pt) * | 2013-02-21 | 2022-07-19 | F. Hoffmann-La Roche Ag | Processos de produção de um composto e compostos |
US20140275562A1 (en) * | 2013-03-13 | 2014-09-18 | Dow Agrosciences Llc | Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto |
WO2014202492A1 (en) * | 2013-06-19 | 2014-12-24 | F. Hoffmann-La Roche Ag | Combination of ro5503781 and capecitabine for cancer therapy |
KR20160009677A (ko) * | 2013-06-19 | 2016-01-26 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 |
JP6346945B2 (ja) * | 2013-06-24 | 2018-06-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 安定な静脈内製剤 |
AU2014286237B2 (en) | 2013-07-03 | 2020-08-20 | F. Hoffmann-La Roche Ag | mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
ES2785203T3 (es) | 2013-12-05 | 2020-10-06 | Hoffmann La Roche | Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA) |
US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
EP3131878A1 (en) * | 2014-04-15 | 2017-02-22 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
KR102599945B1 (ko) | 2014-04-17 | 2023-11-09 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 |
JP6162646B2 (ja) * | 2014-05-27 | 2017-07-12 | 信越化学工業株式会社 | 3,5−ジメチルドデカン酸の製造方法 |
WO2016055497A1 (en) * | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
NZ736450A (en) * | 2015-03-30 | 2022-04-29 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
KR102122469B1 (ko) * | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
CA3048088C (en) | 2016-12-30 | 2021-05-04 | Oriental (Luzhou) Agrochemicals. Co., Ltd. | Method for preparing 2-(cyclohexenylidene) malonic acid derivatives and uses thereof |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
BR112020000553A2 (pt) | 2017-07-11 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | carboxamidas como moduladores de canal de sódio |
CN108586195A (zh) * | 2017-12-27 | 2018-09-28 | 北京汇康博源医药科技有限公司 | 一种5-羟基-7,7-二甲基-2h-茚酮的制备方法 |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CN116459225B (zh) * | 2023-04-26 | 2023-11-10 | 东莞市金美济药业有限公司 | 一种艾拉戈克钠片及其制备工艺 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732902A (en) | 1986-05-23 | 1988-03-22 | Hoffmann-La Roche Inc. | Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents |
TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
JP2001514245A (ja) | 1997-08-28 | 2001-09-11 | ファルマシア・アンド・アップジョン・カンパニー | タンパク質チロシンホスファターゼ阻害剤 |
US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
CN1294120C (zh) * | 2003-10-21 | 2007-01-10 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其应用 |
US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
EP1856123B1 (en) | 2005-02-22 | 2016-02-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
NZ561215A (en) * | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
AU2006258300A1 (en) | 2005-06-17 | 2006-12-21 | Astrazeneca Ab | Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives |
MX2009000285A (es) * | 2006-06-30 | 2009-06-08 | Schering Corp | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. |
EP2104497B1 (de) | 2006-12-06 | 2015-02-25 | Sanofi | Sulfamidderivate als inhibitoren von tafia |
WO2009004383A2 (en) | 2007-07-03 | 2009-01-08 | Astrazeneca Ab | Aza-bicyclohexane compounds useful as anticoagulants |
JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
ES2494390T3 (es) | 2008-06-06 | 2014-09-15 | Sanofi | Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa |
CA2727925A1 (en) | 2008-06-23 | 2009-12-30 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
RU2506257C2 (ru) * | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
US8017607B2 (en) * | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
-
2010
- 2010-02-09 US US12/702,402 patent/US8354444B2/en active Active
-
2011
- 2011-02-04 ES ES11702449.7T patent/ES2629439T3/es active Active
- 2011-02-04 PT PT117024497T patent/PT2534132T/pt unknown
- 2011-02-04 DK DK11702449.7T patent/DK2534132T3/en active
- 2011-02-04 AU AU2011214506A patent/AU2011214506C1/en active Active
- 2011-02-04 BR BR112012019672-3A patent/BR112012019672B1/pt active IP Right Grant
- 2011-02-04 SG SG2012055752A patent/SG182763A1/en unknown
- 2011-02-04 MX MX2012009186A patent/MX2012009186A/es active IP Right Grant
- 2011-02-04 HU HUE11702449A patent/HUE034816T2/en unknown
- 2011-02-04 WO PCT/EP2011/051619 patent/WO2011098398A1/en active Application Filing
- 2011-02-04 NZ NZ601422A patent/NZ601422A/en unknown
- 2011-02-04 KR KR1020127023297A patent/KR101461298B1/ko active IP Right Grant
- 2011-02-04 JP JP2012552343A patent/JP5612710B2/ja active Active
- 2011-02-04 RS RS20170658A patent/RS56163B1/sr unknown
- 2011-02-04 PL PL11702449T patent/PL2534132T3/pl unknown
- 2011-02-04 SI SI201131222T patent/SI2534132T1/sl unknown
- 2011-02-04 EP EP11702449.7A patent/EP2534132B1/en active Active
- 2011-02-04 MY MYPI2012003543A patent/MY165238A/en unknown
- 2011-02-04 PE PE2012001184A patent/PE20121532A1/es active IP Right Grant
- 2011-02-04 CA CA2788236A patent/CA2788236C/en active Active
- 2011-02-04 RU RU2012138257/04A patent/RU2564022C2/ru active
- 2011-02-04 LT LTEP11702449.7T patent/LT2534132T/lt unknown
- 2011-02-04 CN CN2011800089274A patent/CN102753522B/zh active Active
- 2011-02-07 AR ARP110100393A patent/AR080143A1/es active IP Right Grant
- 2011-02-08 TW TW100104166A patent/TWI401243B/zh active
- 2011-04-02 UA UAA201210421A patent/UA107954C2/ru unknown
-
2012
- 2012-08-03 EC ECSP12012083 patent/ECSP12012083A/es unknown
- 2012-08-07 CL CL2012002189A patent/CL2012002189A1/es unknown
- 2012-08-07 CR CR20120410A patent/CR20120410A/es unknown
- 2012-11-29 HK HK12112287.3A patent/HK1171452A1/xx unknown
-
2017
- 2017-06-13 HR HRP20170903TT patent/HRP20170903T1/hr unknown
- 2017-06-23 CY CY20171100673T patent/CY1119049T1/el unknown
-
2018
- 2018-12-13 AR ARP180103640A patent/AR114159A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080143A1 (es) | Pirrolidina-2-carboxamidas sustituidas, composicion farmaceutica que las contiene y su uso en el tratamiento de tastornos oncologicos | |
AR073598A1 (es) | Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer. | |
PE20200723A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
ECSP12011838A (es) | Derivados de la cromenona con actividad anti-tumoral | |
PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
UY35142A (es) | Derivados de triazolopirazinas como inhibidores de brd4 | |
UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
DOP2015000170A (es) | Compuestos químicos | |
UY32432A (es) | Compuestos de pirimidina fusionada como inhibidores de akt | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
CO6650348A2 (es) | Triazolopiridinas sustituidas | |
ECSP15013883A (es) | Benzamidas | |
CR20140037A (es) | Antagonistas trpm8 y su uso en tratamientos | |
CU20150054A7 (es) | Compuestos 1-carbonitrilo-6-amino aromáticos bicíclicos sustituidos como moduladores selectivos del receptor de andrógenos novedosos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |